Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYR | P14679 | 2/20 | 0.68 |
| ▸ | POLB | P06746 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | G6PD | P11413 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.56 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.56 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.56 |
| ▸ | CA12 | O43570 | 3/20 | 0.55 |
| ▸ | CA9 | Q16790 | 3/20 | 0.55 |
| ▸ | CA1 | P00915 | 2/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16788364 | 1.00 | TYR (0.68) | TYRPOLBKDM4EGAAMAPT | |
| SCHEMBL17366541 | 1.00 | TYR (0.68) | TYRPOLBKDM4EGAAMAPT | |
| SCHEMBL11157080 | 1.00 | TYR (0.68) | TYRPOLBKDM4EGAAMAPT | |
| SCHEMBL16785944 | 1.00 | TYR (0.68) | TYRPOLBKDM4EGAAMAPT | |
| SCHEMBL8656135 | 0.91 | TYR (0.69) | TYRPOLBKDM4EGAAMAPT | |
| SCHEMBL8656862 | 0.91 | TYR (0.69) | TYRPOLBKDM4EGAAMAPT | |
| SCHEMBL28029096 | 0.91 | TYR (0.61) | TYRPOLBKDM4EGAAMAPT | |
| SCHEMBL8656133 | 0.91 | TYR (0.69) | TYRPOLBKDM4EGAAMAPT | |
| SCHEMBL14120458 | 0.91 | POLB (0.67) | TYRPOLBSLC28A3CA12CA9 | |
| SCHEMBL8654192 | 0.91 | TYR (0.69) | TYRPOLBKDM4EGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10004222-B2 | Small molecule ice recrystallization inhibitors and methods of use thereof | THE UNIVERSITY OF OTTAWA (CA) | 2018-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10004222-B2 | Small molecule ice recrystallization inhibitors and methods of use thereof | MCL1, IDH3B, IDH3A | TYR 3135/4885POLB 2780/4885KDM4E 1945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.